Assenagon Asset Management S.A. Buys 3,824 Shares of United Therapeutics Corporation $UTHR

Assenagon Asset Management S.A. boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 18.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,628 shares of the biotechnology company’s stock after purchasing an additional 3,824 shares during the quarter. Assenagon Asset Management S.A. owned about 0.06% of United Therapeutics worth $12,000,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Abich Financial Wealth Management LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $44,000. Finally, Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.8%

NASDAQ:UTHR opened at $522.83 on Friday. The firm has a market capitalization of $22.92 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $549.50. The stock’s 50 day moving average price is $495.95 and its two-hundred day moving average price is $472.65.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the business earned $6.19 earnings per share. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total value of $4,398,585.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,938,901.40. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,115,648.40. This trade represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 356,320 shares of company stock worth $176,808,253 over the last quarter. 10.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of United Therapeutics from $466.00 to $486.00 and gave the company an “equal weight” rating in a research note on Monday, March 23rd. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen upped their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Royal Bank Of Canada raised their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, HC Wainwright lifted their target price on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $549.91.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.